Vaxcyte (PCVX) Non Operating Income (2024 - 2026)

Vaxcyte (PCVX) has reported Non Operating Income for 3 consecutive years, with $25.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non Operating Income fell 37.05% year-over-year to $25.2 million; the TTM figure through Mar 2026 stood at $142.2 million (up 12.64% YoY), while the FY2025 annual figure was $157.0 million, up 48.69% from the prior year.
• Non Operating Income retreated to $25.2 million in Q1 2026 per PCVX's latest filing, from $27.8 million in the prior quarter.
• Across five years, Non Operating Income topped out at $59.6 million in Q2 2025 and bottomed at $19.5 million in Q1 2024.
• Historically, Non Operating Income has averaged $32.0 million across 3 years, with a median of $27.8 million in 2025.
• Annual changes were most pronounced in 2025 — Non Operating Income soared 145.68% — and 2026, when it sank 37.05%.
• Vaxcyte's Non Operating Income stood at $25.1 million in 2024, then advanced by 10.71% to $27.8 million in 2025, then declined by 9.17% to $25.2 million in 2026.
• Business Quant data shows PCVX's Non Operating Income at $25.2 million in Q1 2026, $27.8 million in Q4 2025, and $29.6 million in Q3 2025.